Translate this page to:
In JoVE (1)
Other Publications (1)
Articles by Michael L. Beshiri in JoVE
Genome-wide Analysis using ChIP to Identify Isoform-specific Gene Targets
Michael L. Beshiri1, Abul Islam2, Dannielle C. DeWaal1, William F. Richter1, Jennifer Love3, Nuria Lopez-Bigas2, Elizaveta V. Benevolenskaya1
1Department of Biochemistry and Molecular Genetics, University of Illinois Chicago - UIC, 2Research Unit on Biomedical Informatics, Universitat Pompeu Fabra, 3Genome Technology Core, Whitehead Institute for Biomedical Research
Here we are presenting a chromatin immunoprecipitation (ChIP) procedure for genome-wide location analysis of protein isoforms that differ in a histone-binding domain. We are applying it to ChIP-Seq analysis to identify the targets of the KDM5A/JARID1A/RBP2 histone demethylase.
Other articles by Michael L. Beshiri on PubMed
Loss of the Retinoblastoma Binding Protein 2 (RBP2) Histone Demethylase Suppresses Tumorigenesis in Mice Lacking Rb1 or Men1
Proceedings of the National Academy of Sciences of the United States of America. Aug, 2011 | Pubmed ID: 21788502
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1(+/-) mice and Men1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy.